Observational Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4666-4672
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4666
Figure 1
Figure 1 IgG anti-Epstein-Barr virus according to clinical scenarios in Crohn’s disease patients and healthy controls. New patient (n = 13), remission (n = 13), active disease (n = 10) and control (n = 36). P < 0.05 for new patient vs remission and controls. Values are expressed as mean ± SD.